Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
HAMI3379 is a cysteinyl leukotriene 2 (CysLT2) receptor antagonist (IC50 = 37.9 nM in a radioligand binding assay).1 It is selective for CysLT2 over CysLT1 (IC50 = >30 µM in a radioligand binding assay). HAMI3379 inhibits calcium mobilization induced by leukotriene D4 (LTD4; Item No. 20310) or leukotriene C4 (LTC4; Item No. 20210) in CHO cells expressing human CysLT2 (IC50s = 3.8 and 4.4 nM, respectively). It reverses the LTC4-induced increases in perfusion pressure and decreases in contractility in isolated Langendorff-perfused guinea pig hearts in a concentration-dependent manner. HAMI3379 (0.1 mg/kg) prevents decreases in body weight and neurological deficit scores in a rat model of S. pneumoniae-induced meningitis, as well as reduces infarct volume in a rat model of cerebral ischemia brain injury induced by middle cerebral artery occlusion (MCAO).2,3 It also prevents increases in airway hyperresponsiveness in a mouse model of ovalbumin-induced asthma when administered at a dose of 10 mg/kg.4
WARNING This product is not for human or veterinary use.
1. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT2) receptor. Br. J. Pharmacol. 160(2), 399-409 (2010).
2. Neuroprotective effects of CysLTR antagonist on Streptococcus pneumoniae‑induced meningitis in rats. Exp. Ther. Med. 24(1), 443 (2022).
3. HAMI 3379, a CysLT2R antagonist, dose-
4. Characterization of cysteinyl leukotriene-
Neuroprotective effects of CysLTR antagonist on Streptococcus pneumoniae‑induced meningitis in rats. Exp. Ther. Med. 24(1), 443 (2022).